Page 19 - Pfizer

Pfizer aims for full FDA approval of Covid vaccine for people 16 and above

Pfizer Chief Executive Albert Bourla said in a statement that the companies are aiming to win full regulatory approval in the coming months

Pfizer-BioNTech vaccine is highly effective against variants, studies find

Previous research suggested that B.1.1.7 is more infectious and more deadly than other variants, but that vaccines still worked well against it

Pfizer Covid-19 vaccine linked with fewer asymptomatic infections: Study

People who received the Pfizer Covid-19 vaccine at a US hospital had dramatically lower symptomatic and asymptomatic infections compared with their unvaccinated peers, according to a study

Pfizer-BioNTech start full US approval application for Covid-19 vaccine

If approved, the vaccine will be the first fully approved Covid-19 shot and could help ease vaccine hesitancy due to longer-term data required for an FDA approval

Covid jabs for kids in 2-11 age group: Pfizer to seek approval in Sep

Pfizer will likely seek the US Food and Drug Administration's emergency authorisation to administer its coronavirus vaccine among children between the ages of 2 and 11 in September, media reports

Pfizer lifts sales forecast for coronavirus vaccine to $26 billion

This is reflecting new contracts with governments around the world trying to halt the pandemic through rapid vaccination.

Discussions on with India for 'expedited approval' of Covid vaccine: Pfizer

'We are currently discussing with the Indian government an expedited approval pathway to make our Pfizer-BioNTech vaccine available for use in the country,' says Pfizer CEO in a LinkedIn post

Pfizer donates USD 70 mn worth Covid-19 treatment drugs to India

Global pharma major Pfizer is sending its medicines worth USD 70 million from its distribution centres in the US, Europe and Asia

Single dose of Pfizer vaccine cuts Covid-19 spread by half: Study

Protection against coronavirus seen from about 14 days after vaccination

Unanswered questions

Govt should remove uncertainty about next phase of vaccination

Hope Biden asks Pfizer to allow India develop its vaccines: US Congressman

With millions of lives at stake amid a rapid spread of Covid-19, Indian-American Congressman Ro Khanna said he hoped President Joe Biden would call the Pfizer CEO to let India produce its vaccine

Covid vaccine: Sputnik safest, Pfizer's shot worst? Row over Hungary data

The Russian vaccine has six times lower infection rate than Pfizer's

Centre won't import vaccines, wants states and companies to do so: Report

Two govt officials said New Delhi is now leaving it up to states, companies to sign deals with foreign drugmakers while it buys in bulk most of the output of local producers - SII and Bharat Biotech

Even a single vaccine dose cuts Covid-19 infection rate, new UK study finds

A single dose of either the Oxford/AstraZeneca or Pfizer/BioNTech vaccines, currently being administered in the UK, cut the rate of coronavirus infections by around 65%

Astrazeneca is yellow, Pfizer green: Hungary's Covid vaccine-themed treats

At a patisserie in the small town of Vere­segyhaz, the choice is between a selection of layered mousses with colourful jelly toppings, presented in small glasses, with decorative syringes on top

Govt fast-tracks Covid-19 fight, to start vaccination for 18+ from May 1

States allowed to procure directly from manufacturers; open market supply permitted

Expanding vaccine supply

Some good moves but freer pricing needed

From Sputnik V to Moderna, here's a snapshot of Covid-19 vaccines

Of this list, Sputnik V is already approved in India and Sinovac is unlikely to come in as it does not meet the aforementioned criteria

Another dose of vaccine likely to be needed with 12 months: Pfizer CEO

Pfizer Chief Executive Officer Albert Bourla said people will likely need a third dose of the Pfizer/BioNTech Covid-19 vaccine within 12 months of getting fully inoculated

Decision in 3 working days after foreign Covid-19 vaccine firms apply

Many vaccine makers in talks with govt as India wants a portfolio of products